admin – Page 161 – Get News Story

Migraine Therapeutic Pipeline Witnesses Significant Expansion as 30+ Pharma Companies Compete in Advanced Drug Development | DelveInsight

DelveInsight’s, “Migraine Pipeline Insight 2026” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Migraine pipeline landscape. It covers the Migraine pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Migraine Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead in understanding the Migraine Treatment Landscape @ Migraine Pipeline Outlook

Key Takeaways from the Migraine Pipeline Report

On April 21, 2026- Pfizer initiated a study is being conducted to evaluate the efficacy and tolerability of rimegepant in a population of adults that are unsuitable for triptan medications due to a previous intolerance, lack of efficacy, or contraindication (including a history of clinically-relevant cardiovascular disease).
On April 15, 2026- H. Lundbeck A/S conducted a study for participants aged 6 to 17 with migraine who completed either studies 19356A (NCT04965675) (chronic migraine [CM] study in adolescents) or 19357A (episodic migraine [EM] study in children and adolescents). All participants who complete the Week 12 visit of the respective lead-in study will be offered participation in this open-label extension (OLE) study, unless there is a safety concern precluding a participant’s participation in the study.
DelveInsight’s Migraine pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Migraine treatment.
The leading Migraine Companies such as Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, Allodynic Therapeutics, Vaxxinity, AbbVie, Pulmatrix, AEON Biopharma, Eli Lilly and Company, Trevena, Xoc Pharmaceuticals, Pharmaleads, Pear Therapeutics and others.
Promising Migraine Pipeline Therapies such as ALD403 (Eptinezumab), Ketorolac, Sumatriptan, divalproex sodium, Erenumab, GSK1838262, ALD403 and others.
Stay informed about the cutting-edge advancements in Migraine Treatments @ Migraine Clinical Trials Assessment

Migraine Overview

Migraine is a neurological pain condition that affects millions of people. It is the most common neurological disease that has significant effects on the brain and consequently on behaviors associated with repeated migraine attacks. The stress of migraine is associated with premigraine, intermigraine, and postmigraine processes. Understanding of migraine includes how normally non-painful stimuli such as light may exacerbate the pain of migraine and how the migraine headache may produce changes in skin sensitivity (allodynia) that can involve the whole body. Alterations in the brain’s function and structure, as revealed by advanced imaging techniques, have provided new insights into the mechanisms of the disease

Migraine Emerging Drugs Profile

AXS-07: Axsome Therapeutics

AXS-07 is a novel, oral, rapidly absorbed, multi-mechanistic, investigational medicine. AXS-07 consists of MoSEIC (Molecular Solubility Enhanced Inclusion Complex) meloxicam and rizatriptan. AXS-07 is thought to act by inhibiting Calcitonin gene-related peptide (CGRP) release, reversing CGRP-mediated vasodilation, and inhibiting neuroinflammation, pain signal transmission, and central sensitization. Meloxicam is a new molecular entity for migraine enabled by MoSEIC™ technology, which results in rapid absorption of meloxicam while maintaining a long plasma half-life. AXS-07 is currently being developed for the acute treatment of migraine. The product is in the NDA submitted phase of development.

STS-101: Satsuma Pharmaceuticals

STS101 combines the Satsuma powder technology with an easy-to-use nasal delivery device to create a reliable and convenient DHE product potentially able to provide the unique clinical advantages of DHE while overcoming the shortcomings of existing DHE products. TS101 has a number of key advantages that we believe may provide significant benefits over other acute treatments for migraine and result in robust and consistent clinical performance. These advantages arise from our proprietary dry-powder formulation, which incorporates a mucoadhesive drug carrier and engineered drug particle technologies, and our proprietary nasal delivery device. STS101 is an investigational product that is currently being evaluated in Phase 3 clinical trials for the acute treatment of migraine and is not approved by the U.S. Food and Drug Administration.

Zavegepant: Biohaven Pharmaceuticals

Zavegepant (BHV-3500) is a third generation, high affinity, selective and structurally unique, small molecule CGRP receptor antagonist. The chemical properties of zavegepant make the product candidate potentially suitable for multiple routes of delivery, including nasal, subcutaneous, inhalation or oral administration.It is currently in Phase III stage of development for Migraine and is being developed by Biohaven Pharmaceuticals.

TNX1900: Tonix Pharmaceuticals

TNX-1900(Oxytocin), Tonix’s proprietary potentiated intranasal oxytocin is in the pre-Investigational New Drug (IND) stage and is currently being studied as a candidate for prophylaxis of chronic migraine. Oxytocin is a naturally occurring human hormone that acts as a neurotransmitter in the brain. In clinical and preliminary research, it has been observed that increased oxytocin levels can relieve headaches. When oxytocin is delivered via the nasal route, it results in enhanced binding to receptors on neurons in the trigeminal system, inhibiting transmission of pain signals. Intranasal oxytocin has been well tolerated in several clinical trials in adults and children and has been shown to block calcitonin gene-related peptide (CGRP) release in animals, a pathway known to be critical to the pathogenesis of migraine attacks. TNX-1900 is believed to interrupt pain signals at the trigeminal ganglia by suppressing electrical impulses, a potentially different activity than drugs that just block CGRP. TNX-1900 is an investigational new drug and has not been approved for any indication.

The Migraine pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Migraine with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Migraine Treatment.
Migraine Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Migraine Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Migraine market.

Get a detailed analysis of the latest innovations in the Migraine pipeline @ Migraine Unmet Needs

Migraine Companies

Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, Allodynic Therapeutics, Vaxxinity, AbbVie, Pulmatrix, AEON Biopharma, Eli Lilly and Company, Trevena, Xoc Pharmaceuticals, Pharmaleads, Pear Therapeutics and others.

Migraine pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal

Migraine Products have been categorized under various Molecule types such as

Oligonucleotide
Peptide
Small molecule

Stay informed about how we’re transforming the future of neurology @ Migraine Market Drivers and Barriers, and Future Perspectives

Scope of the Migraine Pipeline Report

Coverage- Global
Migraine Companies- Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, Allodynic Therapeutics, Vaxxinity, AbbVie, Pulmatrix, AEON Biopharma, Eli Lilly and Company, Trevena, Xoc Pharmaceuticals, Pharmaleads, Pear Therapeutics and others.
Migraine Pipeline Therapies- ALD403 (Eptinezumab), Ketorolac, Sumatriptan, divalproex sodium, Erenumab, GSK1838262, ALD403 and others.
Migraine Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Migraine Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Read the full details of Migraine Pipeline on our website @ Migraine Emerging Drugs and Companies

Table of Content

Introduction
Executive Summary
Migraine: Overview
Pipeline Therapeutics
Therapeutic Assessment
Migraine– DelveInsight’s Analytical Perspective
Late Stage Products (Pre-Registration)
AXS-07: Axsome Therapeutics
Drug profiles in the detailed report…..
Last Stage Products (Phase III)
STS-101: Satsuma Pharmaceuticals
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
TNX1900: Tonix Pharmaceuticals
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Migraine Key Companies
Migraine Key Products
Migraine – Unmet Needs
Migraine – Market Drivers and Barriers
Migraine – Future Perspectives and Conclusion
Migraine Analyst Views
Migraine Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/migraine-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Migraine Therapeutic Pipeline Witnesses Significant Expansion as 30+ Pharma Companies Compete in Advanced Drug Development | DelveInsight

Hidradenitis Suppurativa Pipeline Gains Momentum: 24+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s, “Hidradenitis Suppurativa Pipeline Insight 2026” report provides comprehensive insights about 24+ companies and 24+ pipeline drugs in Hidradenitis Suppurativa pipeline landscape. It covers the Hidradenitis Suppurativa Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hidradenitis Suppurativa pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead in understanding the Hidradenitis Suppurativa Treatment Landscape. Click here to read more @ https://www.delveinsight.com/sample-request/hidradenitis-suppurativa-pipeline-insight

Key Takeaways from the Hidradenitis Suppurativa Pipeline Report

On June 03, 2026- Novartis Pharmaceuticals initiated a study to evaluate efficacy, and safety of two dosing regimens of secukinumab (AIN457), 300 mg every four weeks (Q4W) and every two weeks (Q2W), in Chinese adult patients with moderate to severe hidradenitis suppurativa (HS).
On June 03, 2026- AbbVie highlighted a study will compare lutikizumab versus placebo for the treatment of adult and adolescent participants with the signs and symptoms of moderate to severe HS. Lutikizumab is an investigational drug being developed for the treatment of HS. During Period 1 of the study, participants will placed in 1 of 2 groups called treatment arms. There is a 1 in 2 chance that participants will be assigned to placebo.
On June 01, 2026- Incyte Corporation announced a phase 3b, Multicenter, Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib.
DelveInsight’s Hidradenitis Suppurativa pipeline report depicts a robust space with 24+ active players working to develop 24+ pipeline therapies for Hidradenitis Suppurativa treatment.
The leading Hidradenitis Suppurativa Companies such as InflaRx, Novartis, UCB, ChemoCentryx, Eli Lilly and Company, Janssen Biotech, AbbVie, Pfizer, Amgen, Incyte Corporation, CSL Behring, Kymera Therapeutics, Lytix Biopharma, Aclaris Therapeutics, Boehringer Ingelheim, and Azora Therapeutics and others.
Promising Hidradenitis Suppurativa Pipeline Therapies such as Remibrutinib Dose A, AVTX-009, Izokibep, Bimekizumab, Sonelokimab (M1095), Adalimumab and others.

Gain in-depth knowledge of key Hidradenitis Suppurativa Emerging Therapies @ Hidradenitis Suppurativa Clinical Trials Assessment

Hidradenitis Suppurativa Overview

Hidradenitis suppurativa (HS), also called acne inversus, is a chronic inflammatory skin condition with lesions including deep-seated nodules and abscesses, draining tracts, and fibrotic scars. These lesions most commonly occur in intertriginous areas and areas rich in apocrine glands. Among the most common are axillary, groin, perianal, perineal, and inframammary locations. This activity reviews the cause, presentation, and complications of Hidradenitis suppurativa and highlights the role of the interprofessional team in its management. The pathologic process of HS begins when a defective hair follicle becomes occluded and ruptures, spilling its contents, including keratin and bacteria, into the surrounding dermis. A chemotactic inflammatory response by surrounding neutrophils and lymphocytes can lead to abscess formation and subsequent destruction of the pilosebaceous unit and other adjacent structures. Prognosis is variable. There is no cure for this condition. The prognosis worsens if there is a delay in diagnosis and treatment during the early stages of the disease, and also if comorbid conditions of smoking and obesity (if present) are not addressed and improved.

Hidradenitis Suppurativa Emerging Drugs Profile

Vilobelimab: InflaRx

Vilobelimab is a first-in-class monoclonal anti-human complement factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood. Thus, vilobelimab leaves the formation of the membrane attack complex (C5b-9) intact as an important defense mechanism, which is not the case for molecules blocking the cleavage of C5. Vilobelimab has been demonstrated to control the inflammatory response driven tissue and organ damage by specifically blocking C5a as a key “amplifier” of this response in pre-clinical studies. Vilobelimab is believed to be the first monoclonal anti-C5a antibody introduced into clinical development. Approximately 300 people have been treated with vilobelimab in clinical trials, and the antibody has been shown to be well tolerated. Vilobelimab is currently being developed for various indications, including Hidradenitis Suppurativa, ANCA-associated vasculitis, Pyoderma Gangraenosum, cancer and severe COVID‑19.

Secukinumab: Novartis

Secukinumab is the first and only fully human biologic that directly inhibits interleukin-17A (IL-17A), an important cytokine involved in the inflammation of psoriatic arthritis (PsA), moderate to severe plaque psoriasis, ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA)12,13. Cosentyx is a proven medicine and has been studied clinically for more than 14 years. The medicine is backed by robust evidence, including 5 years of clinical data in adults supporting long-term safety and efficacy across moderate to severe plaque psoriasis, PsA and AS14-20. These data strengthen the position of Cosentyx as a treatment across AS, nr-axSpA, PsA and moderate to severe plaque psoriasis, supported by more than 500,000 patients treated worldwide since launch in 2015.

Avacopan: ChemoCentryx

Avacopan, approved by the FDA as an adjunctive treatment of ANCA-associated vasculitis, is a first-in-class, orally-administered small molecule that employs a novel, highly targeted mode of action in complement-driven autoimmune and inflammatory diseases. While the precise mechanism in ANCA vasculitis has not been definitively established, Avacopan, by blocking the complement 5a receptor (C5aR) for the pro-inflammatory complement system fragment known as C5a on destructive inflammatory cells such as blood neutrophils, is presumed to arrest the ability of those cells to do damage in response to C5a activation, which is known to be the driver of ANCA vasculitis. Avacopan’s selective inhibition of only the C5aR leaves the beneficial C5a pathway through the C5L2 receptor functioning normally. ChemoCentryx is also developing TAVNEOS for the treatment of patients with C3 glomerulopathy (C3G), hidradenitis suppurativa (HS) and Lupus Nephritis (LN).

Imsidolimab: AnaptysBio

Imsidolimab, previously known as ANB019, is an antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, which AnaptysBio plans to initially develop as a potential first-in-class therapy for patients suffering from generalized pustular psoriasis, or GPP, EGFR-mediated skin toxicity, ichthyosis, hidradenitis suppurativa and acne.

Spesolimab: Boehringer Ingelheim

Spesolimab is a novel, humanized, selective antibody that blocks the activation of the interleukin-36 receptor (IL-36R), a signaling pathway within the immune system shown to be involved in the pathogeneses of several autoimmune diseases, including GPP. Spesolimab is also under investigation for the prevention of GPP flares and for the treatment of other neutrophilic skin diseases, such as palmoplantar pustulosis (PPP) and hidradenitis suppurativa (HS).

Hidradenitis Suppurativa Market Drivers

Advancements in Research and Development
Rise in awareness about the disease

Hidradenitis Suppurativa Market Barriers

Stigma and Patient Reluctance
Complexity of the disease

The Hidradenitis Suppurativa Pipeline Report Provides Insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Hidradenitis Suppurativa with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hidradenitis Suppurativa Treatment.
Hidradenitis Suppurativa Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Hidradenitis Suppurativa Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hidradenitis Suppurativa market

Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Hidradenitis Suppurativa Unmet Needs

Hidradenitis Suppurativa Companies

InflaRx, Novartis, UCB, ChemoCentryx, Eli Lilly and Company, Janssen Biotech, AbbVie, Pfizer, Amgen, Incyte Corporation, CSL Behring, Kymera Therapeutics, Lytix Biopharma, Aclaris Therapeutics, Boehringer Ingelheim, and Azora Therapeutics and others.

Hidradenitis Suppurativa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Hidradenitis Suppurativa Products have been categorized under various Molecule types such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

See the latest progress in drug development and clinical research @ Hidradenitis Suppurativa Market Drivers and Barriers, and Future Perspectives

Scope of the Hidradenitis Suppurativa Pipeline Report

Coverage- Global
Hidradenitis Suppurativa Companies- InflaRx, Novartis, UCB, ChemoCentryx, Eli Lilly and Company, Janssen Biotech, AbbVie, Pfizer, Amgen, Incyte Corporation, CSL Behring, Kymera Therapeutics, Lytix Biopharma, Aclaris Therapeutics, Boehringer Ingelheim, Azora Therapeutics and others.
Hidradenitis Suppurativa Pipeline Therapies- Remibrutinib Dose A, AVTX-009, Izokibep, Bimekizumab, Sonelokimab (M1095), Adalimumab and others.
Hidradenitis Suppurativa Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Hidradenitis Suppurativa Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Access the Full Hidradenitis Suppurativa Pipeline Analysis Today! @ Hidradenitis Suppurativa Drugs and Companies

Table of Content

Introduction
Executive Summary
Hidradenitis Suppurativa: Overview
Pipeline Therapeutics
Therapeutic Assessment
Hidradenitis Suppurativa – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Vilobelimab: InflaRx
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Spesolimab: Boehringer Ingelheim
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Drug name: Company name
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
AT193: Azora Therapeutics
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Hidradenitis Suppurativa Key Companies
Hidradenitis Suppurativa Key Products
Hidradenitis Suppurativa – Unmet Needs
Hidradenitis Suppurativa – Market Drivers and Barriers
Hidradenitis Suppurativa – Future Perspectives and Conclusion
Hidradenitis Suppurativa Analyst Views
Hidradenitis Suppurativa Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hidradenitis Suppurativa Pipeline Gains Momentum: 24+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

Myelofibrosis Pipeline Accelerates as 50+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s, “Myelofibrosis Pipeline Insights 2026” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Myelofibrosis pipeline landscape. It covers the Myelofibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelofibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download DelveInsight’s comprehensive Myelofibrosis Pipeline Report to explore emerging therapies @ https://www.delveinsight.com/sample-request/myelofibrosis-pipeline-insight

Key Takeaways from the Myelofibrosis Pipeline Report

On June 04, 2026, Novartis Pharmaceuticals initiated a phase 3 trial is to evaluate whether treatment with pelabresib in combination with ruxolitinib leads to improved clinical outcomes compared to ruxolitinib alone in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF) who have not previously received Janus kinase (JAK) inhibitor therapy.
On June 02, 2026, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. highlighted a Phase II Clinical Trial of TQ05105 Tablets Versus Hydroxyurea Tablets in the Treatment of Moderate and High Risk Myelofibrosis.
DelveInsight’s Myelofibrosis pipeline report depicts a robust space with 35+ active players working to develop 40+ pipeline therapies for Myelofibrosis treatment.
The leading Myelofibrosis Companies such as PharmaEssentia Corporation, iOnctura, Prelude Therapeutics, Cellenkos, Ajax Therapeutics, Eilean Therapeutics, Phoenix Molecular Designs, Ryvu Therapeutics, Disc Medicine, Sumitomo Pharma, CERo Therapeutics, Stemline Therapeutics, Incyte Corporation, Takeda, Syntara Limited, Opna Bio, Epigenetix, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., GluBio Therapeutics, Telios Pharma, Inc. and others.
Promising Myelofibrosis Therapies such as Momelotinib, Luspatercept, Bomedemstat, Pacritinib, RVU120, Ruxolitinib, and others.

Access DelveInsight’s in-depth Myelofibrosis Pipeline Analysis for a closer look at promising breakthroughs @ Myelofibrosis Clinical Trials and Studies

Myelofibrosis Overview

Myelofibrosis is a chronic blood cancer in which clonal abnormalities in hematopoietic stem cells drive progressive bone marrow fibrosis, resulting in ineffective blood cell production and clinical features such as anemia, splenomegaly, and fatigue. It is classified as a BCR-ABL1–negative myeloproliferative neoplasm and may arise de novo or evolve from antecedent conditions like polycythemia vera or essential thrombocythemia. The disease is strongly associated with driver mutations in JAK2, CALR, or MPL, which lead to persistent activation of the JAK-STAT signaling pathway and a pro-inflammatory cytokine milieu.

Myelofibrosis Emerging Drugs

Ropeginterferon alfa-2b: PharmaEssentia Corporation

Ropeginterferon alfa-2b is a long-acting, mono-pegylated interferon designed for sustained activation of interferon signaling with improved tolerability and convenient dosing compared to earlier interferons. It exerts antiproliferative and immunomodulatory effects, helping to suppress malignant hematopoietic clones and restore more normal bone marrow function. The drug is currently being studied in a Phase III clinical trial for the treatment of Myelofibrosis.

Roginolisib: iOnctura

Roginolisib is an orally available, first-in-class allosteric modulator of PI3Kδ, distinguished by its unique binding mode that alters the protein’s 3D conformation and selectively inhibits its activity. By targeting the PI3Kδ isoform commonly dysregulated in cancers and expressed in immunosuppressive cells, it aims to reverse tumor-associated immune suppression while directly inhibing malignant cell proliferation. In myelofibrosis, Roginolisib may help counteract immune-mediated resistance mechanisms that limit current therapies. It is currently being evaluated in a Phase II clinical trial for the treatment of Myelofibrosis.

RVU120: Ryvu Therapeutics

RVU120 is an oral, selective inhibitor of CDK8 and CDK19, key regulators of transcriptional pathways involved in oncogenesis and inflammation. In Myelofibrosis, it modulates aberrant signaling such as STAT-driven pathways, helping to suppress malignant hematopoietic cell proliferation. The drug has demonstrated potential disease-modifying activity, including reduction of inflammatory cytokines and fibrosis-associated signaling. RVU120 is currently in Phase II of its clinical development, with early studies indicating activity in patients resistant or refractory to JAK inhibitor therapies.

PRT12396: Prelude Therapeutics

PRT12396 is a mutant-selective JAK2V617F inhibitor being developed for the treatment of patients with certain myeloproliferative neoplasms (MPNs). It has received Investigational New Drug (IND) clearance from the US Food and Drug Administration, enabling clinical evaluation in advanced malignancies, including hematologic cancers. It is currently being evaluated in a Phase I clinical trial for the treatment of Myelofibrosis.

The Myelofibrosis Pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Myelofibrosis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myelofibrosis Treatment.
Myelofibrosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Myelofibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myelofibrosis market.

Explore DelveInsight’s expert-driven report today! @ Myelofibrosis Unmet Needs

Myelofibrosis Companies

PharmaEssentia Corporation, iOnctura, Prelude Therapeutics, Cellenkos, Ajax Therapeutics, Eilean Therapeutics, Phoenix Molecular Designs, Ryvu Therapeutics, Disc Medicine, Sumitomo Pharma, CERo Therapeutics, Stemline Therapeutics, Incyte Corporation, Takeda, Syntara Limited, Opna Bio, Epigenetix, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., GluBio Therapeutics, Telios Pharma, Inc. and others.

Myelofibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Myelofibrosis Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming Myelofibrosis Therapies @ Myelofibrosis Market Drivers and Barriers, and Future Perspectives

Scope of the Myelofibrosis Pipeline Report

Coverage- Global
Myelofibrosis Companies- PharmaEssentia Corporation, iOnctura, Prelude Therapeutics, Cellenkos, Ajax Therapeutics, Eilean Therapeutics, Phoenix Molecular Designs, Ryvu Therapeutics, Disc Medicine, Sumitomo Pharma, CERo Therapeutics, Stemline Therapeutics, Incyte Corporation, Takeda, Syntara Limited, Opna Bio, Epigenetix, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., GluBio Therapeutics, Telios Pharma, Inc. and others.
Myelofibrosis Therapies- Momelotinib, Luspatercept, Bomedemstat, Pacritinib, RVU120, Ruxolitinib, and others.
Myelofibrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Myelofibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find out in DelveInsight’s exclusive Myelofibrosis Pipeline Report @ Myelofibrosis Emerging Drugs and Major Companies

Table of Content

Introduction
Executive Summary
Myelofibrosis: Overview
Myelofibrosis Pipeline Therapeutics
Myelofibrosis Therapeutic Assessment
Myelofibrosis – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Ropeginterferon alfa-2b: PharmaEssentia Corporation
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Roginolisib: iOnctura
Drug profiles in the detailed report…..
PRT12396: Prelude Therapeutics
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Myelofibrosis Key Companies
Myelofibrosis Key Products
Myelofibrosis- Unmet Needs
Myelofibrosis- Market Drivers and Barriers
Myelofibrosis- Future Perspectives and Conclusion
Myelofibrosis Analyst Views
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Myelofibrosis Pipeline Accelerates as 50+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

Psoriasis Pipeline Expands as 65+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s “Psoriasis Pipeline Insight, 2026” report provides comprehensive insights about 65+ companies and 75+ pipeline drugs in the Psoriasis pipeline landscape. It covers the Psoriasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Psoriasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Learn more about our innovative Psoriasis Pipeline today! @ https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight

Key Takeaways from the Psoriasis Pipeline Report

On June 03, 2026- Haisco Pharmaceutical Group Co., Ltd. initiated a phase I/II clinical study aims to comprehensively evaluate HSK44459 cream’s potential as a treatment for plaque psoriasis, while also characterizing its safety, tolerability, and PK properties in both healthy individuals and patient populations.
On June 03, 2026- Bristol-Myers Squibb highlighted a study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community setting.
DelveInsight’s Psoriasis pipeline report depicts a robust space with 65+ active players working to develop 75+ pipeline therapies for Psoriasis treatment.
The leading Psoriasis Companies such as Can-Fite Biopharma, Huabo Biopharm Co., Ltd., MoonLake Immunotherapeutics, E-nitiate Biopharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, BioRay Pharmaceutical Co., Ltd., SFA Therapeutics, Rubedo Life Sciences, Inc. and others.
Promising Psoriasis Pipeline Therapies such as Hypericin, EDP1815, Cetaphil, AX-158, HAT1 topical solution, Calcipotriol, ARQ-151 cream 0.3%, MP1032, Risankizumab, Certolizumab Pegol, and others.

Download for updates and be a part of the revolution in Immunological and Autoimmune Disorders care @ Psoriasis Clinical Trials Assessment

Psoriasis Overview

Psoriasis is a chronic, inflammatory skin disorder characterized by the rapid buildup of skin cells, leading to red, scaly patches commonly found on the elbows, knees, scalp, and back. This condition is driven by an overactive immune response that accelerates skin cell production, creating raised, itchy plaques. While the exact cause remains unknown, genetics, immune system dysfunction, and environmental triggers such as stress, infections, or injuries play significant roles. Psoriasis can range from mild to severe, impacting quality of life and often associated with other health issues like psoriatic arthritis, cardiovascular disease, and mental health challenges.

Psoriasis Emerging Drugs Profile

Piclidenoson: Can-Fite Biopharma

Piclidenoson, generically known as IB-MECA (methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl]-b-D-ribofuronamide), is an oral small molecule drug formulated in a tablet. Piclidenoson mechanism of action is A3AR mediated and includes modulation of key signaling proteins, such as PI3K, PKA, PKB/Akt, IKK and NF-kB, resulting in de-regulation of the Wnt/β-catenin pathway and inhibition of inflammatory cytokine production. Currently, the drug is in Phase III stage of its development for the treatment of Psoriasis.

Sonelokimab: MoonLake Immunotherapeutics

Sonelokimab is an investigational Nanobody® developed by MoonLake Immunotherapeutics for treating inflammatory diseases. It targets IL-17A and IL-17F cytokines, inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers, and includes a domain that binds to human albumin to enhance tissue penetration . In Phase 2 trials, sonelokimab demonstrated superior efficacy compared to AbbVie’s Humira in psoriatic arthritis, with higher percentages of patients achieving significant improvements in joint swelling and psoriasis severity . Additionally, it showed promising results in treating hidradenitis suppurativa, meeting the HiSCR75 endpoint in the Phase 2 MIRA trial. Currently, MoonLake is conducting Phase III trials for both conditions and exploring its use in other inflammatory diseases such as palmoplantar pustulosis and axial spondyloarthritis.

QY101: E-nitiate Biopharmaceuticals

QY101 is a topical ointment developed by E-nitiate Biopharmaceuticals for treating inflammatory skin conditions like atopic dermatitis and plaque psoriasis. It functions as a non-steroidal, non-hormonal phosphodiesterase 4 (PDE4) inhibitor, aiming to reduce inflammation by targeting overactive PDE4 pathways. Preclinical studies have demonstrated favorable pharmacokinetics, strong efficacy, and high safety, making it suitable for various age groups, including children. Currently, QY101 is undergoing a Phase II clinical trial in China for plaque psoriasis, following the completion of a Phase I trial in healthy volunteers. The company is also exploring additional formulations, such as an inhaler, through licensing collaborations.

SFA 002: SFA Therapeutics

SFA-002, an IL-10 up-regulator in immune cells, is approaching Phase 2 clinical trials and has shown promising Phase 1a and Phase Ib results for the treatment of psoriasis. SFA-002 met its primary endpoint of safety in the Phase 1b clinical trial. No treatment related adverse events or toxicities were observed during the treatment period, and no rebound effects were observed. SFA Therapeutics has filed its annual safety update with the U.S. Food and Drug Administration. SFA-002 met its exploratory endpoint of efficacy. Patients administered SFA-002 demonstrated statistically significant Psoriasis Area and Severity Index (PASI) percentage change and Investigator Global Assessment (IGA) score improvements compared to placebo. PASI is a tool used to measure the severity and extent of psoriasis while IGA is a standardized rating system of patient disease severity. The study was designed in two cohorts, to evaluate two different formulations. Currently the drug is in Phase II/III stage of its development for the treatment of Psoriasis.

RLS-1496: Rubedo Life Sciences, Inc

RLS-1496 is a first-in-class GPX4 modulator that targets aging cells and surrounding tissues being developed by Rubedo Life Sciences for the treatment of dermatological conditions and other chronic age-related diseases. It is a topical medicine designed to target aging cells, specifically senescent cells, in skin lesions of chronic atopic dermatitis and chronic psoriasis. Currently the drug is in Preclinical stage of its development for the treatment of Psoriasis.

The Psoriasis Pipeline Report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Psoriasis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Psoriasis Treatment.
Psoriasis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Psoriasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Psoriasis market.

Learn more about Psoriasis Drugs opportunities in our groundbreaking Research projects @ Psoriasis Unmet Needs

Psoriasis Companies

Can-Fite Biopharma, Huabo Biopharm Co., Ltd., MoonLake Immunotherapeutics, E-nitiate Biopharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, BioRay Pharmaceutical Co., Ltd., SFA Therapeutics, Rubedo Life Sciences, Inc. and others.

Psoriasis Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Psoriasis Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Stay informed about how we’re transforming the future of Immunological and Autoimmune Disorders @ Psoriasis Market Drivers and Barriers, and Future Perspectives

Scope of the Psoriasis Pipeline Report

Coverage- Global
Psoriasis Companies- Can-Fite Biopharma, Huabo Biopharm Co., Ltd., MoonLake Immunotherapeutics, E-nitiate Biopharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, BioRay Pharmaceutical Co., Ltd., SFA Therapeutics, Rubedo Life Sciences, Inc. and others.
Psoriasis Pipeline Therapies- Hypericin, EDP1815, Cetaphil, AX-158, HAT1 topical solution, Calcipotriol, ARQ-151 cream 0.3%, MP1032, Risankizumab, Certolizumab Pegol, and others.
Psoriasis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Psoriasis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Read the full details of Psoriasis Pipeline on our website @ Psoriasis Emerging Drugs and Companies

Table of Contents

Introduction
Executive Summary
Psoriasis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Psoriasis– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Piclidenoson: Can-Fite Biopharma
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
SFA 002: SFA Therapeutics
Early Stage Products (Phase I/II)
Drug Name: Company Name
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
RLS-1496: Rubedo Life Sciences, Inc
Inactive Products
Psoriasis Key Companies
Psoriasis Key Products
Psoriasis- Unmet Needs
Psoriasis- Market Drivers and Barriers
Psoriasis- Future Perspectives and Conclusion
Psoriasis Analyst Views
Psoriasis Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Psoriasis Pipeline Expands as 65+ Companies Driving Innovation in the Therapeutics | DelveInsight

Rheumatoid Arthritis Pipeline Shows Strong Momentum as 75+ Pharma Companies in the Race | DelveInsight

DelveInsight’s “Rheumatoid Arthritis Pipeline Insight 2026” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in the Rheumatoid Arthritis (RA) pipeline landscape. It covers the Rheumatoid Arthritis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Rheumatoid Arthritis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Rheumatoid Arthritis Pipeline @ https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight

Key Takeaways from the Rheumatoid Arthritis Pipeline Report

On June 04, 2026- AbbVie initiated a study currently includes 3 substudies evaluating different treatments in participants with RA. Substudy 1 will evaluate lutikizumab monotherapy (treatment given alone) compared to placebo (looks like the study treatment but contains no medicine). Substudy 2 will evaluate ravagalimab monotherapy compared to placebo and Substudy 3 will evaluate lutikizumab and ravagalimab combination therapy (treatments given together) compared to placebo. Approximately 180 participants who have failed 1 or 2 biologic/targeted synthetic disease-modifying antirheumatic drug (tsDMARD) therapies will be enrolled in the study at approximately 65 sites worldwide.
On June 01, 2026- Hoffmann-La Roche highlighted a phase II study will assess the efficacy and safety of Afimkibart (also known as RO7790121) compared with placebo in participants with moderate to severe rheumatoid arthritis (RA) who have an inadequate response or intolerance to TNF and/or JAK inhibitors.
DelveInsight’s Rheumatoid Arthritis Pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Rheumatoid Arthritis treatment.
The leading Rheumatoid Arthritis Companies such as Gedeon Richter, mAbxience Research S.L., AnaptysBio, Inc, Istesso, Synact Pharma, Sanofi, AstraZeneca, Cullinan Therapeutics, Sonoma Biotherapeutics, Immunovant, Inc, Janssen Research & Development, LLC, Ernexa Therapeutics Inc., Kymera Therapeutics, Inc., Eli Lilly and Company, Rise Therapeutics LLC, Artiva Biotherapeutics, Inc., SinoMab BioScience Limited, ECM Therapeutics, Hangzhou Highlightll Pharmaceutical Co., Ltd, Beijing VDJBio Co., LTD., AbbVie, ILAb Co., Ltd., Sonoma Biotherapeutics, Inc., Gilead Sciences, Zenas BioPharma (USA), LLC, Flerie AB, Spyre Therapeutics, Inc, Candid Therapeutics, Inc., LAPIX Therapeutics and others.
Promising Rheumatoid Arthritis Pipeline Therapies such as BMS-582949, Etanercept, Lutikizumab, Ravagalimab, Filgotinib Maleate, IMVT-1402, TLL-018, CPL409116, LY3541860 and others.

Get insights into clinical trials, emerging therapies, and leading companies with Rheumatoid Arthritis @ Rheumatoid Arthritis Treatment Drugs

The Rheumatoid Arthritis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Rheumatoid Arthritis Pipeline Report also highlights the unmet needs with respect to the Rheumatoid Arthritis.

Rheumatoid Arthritis Overview

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disorder primarily affecting synovial joints, often starting symmetrically in small peripheral joints and progressing to larger joints if left untreated. It results from a complex interaction between genetic predisposition and environmental factors such as smoking. RA leads to persistent inflammation, joint destruction, cartilage loss, and bone erosion, contributing to long-term disability and increased mortality if not adequately managed. The disease is classified as early RA when symptoms last fewer than six months, and as established RA when they persist longer. Diagnosis can be challenging due to the lack of a definitive laboratory test, necessitating a comprehensive clinical evaluation. Management includes both pharmacological interventions, particularly early use of disease-modifying anti-rheumatic drugs (DMARDs), and non-pharmacological strategies like physical therapy, counseling, and patient education to reduce morbidity and enhance quality of life.

Rheumatoid Arthritis Emerging Drugs Profile

RGB-19: Gedeon Richter

RGB-19, developed by Gedeon Richter in collaboration with Mochida Pharmaceutical, is a biosimilar version of tocilizumab, a monoclonal antibody that inhibits interleukin-6 (IL-6) signaling, which plays a central role in the inflammation associated with rheumatoid arthritis. By targeting IL-6, RGB-19 aims to reduce inflammation and alleviate symptoms in patients with rheumatoid arthritis and other immune-mediated conditions. As a biosimilar to the reference product RoActemra®, RGB-19 is designed to offer comparable efficacy and safety, while providing a more affordable therapeutic option to patients worldwide, thereby expanding access to this important biological treatmentCurrently, the drug is registered for the treatment of Rheumatoid Arthritis (RA).

MB04: mAbxience Research S.L.

MB04, developed by mAbxience Research S.L., is a biosimilar to etanercept designed for the treatment of rheumatoid arthritis and other autoimmune diseases. It is an Fc fusion protein that targets and inhibits both tumor necrosis factor alpha (TNF-α) and lymphotoxin alpha (LTα, also known as TNF-β), key cytokines involved in the inflammatory processes underlying rheumatoid arthritis. By blocking these cytokines, MB04 aims to reduce inflammation and alleviate symptoms associated with immune-mediated joint damage. As a biosimilar, MB04 is intended to offer comparable efficacy and safety to the reference biologic (Enbrel®), while potentially improving access and affordability for patients requiring long-term management of rheumatoid arthritis. Currently, the drug is in Phase III stage of its development for the treatment of Rheumatoid Arthritis (RA).

Rosnilimab: AnaptysBio, Inc

Rosnilimab is a novel therapeutic antibody that directly targets PD-1, a co-inhibitory receptor preferentially expressed on the surface of activated T cells, which broadly impacts the pathogenic drivers of inflammatory diseases such as RA and UC. Rosnilimab is a targeted therapy designed to deplete PD-1high T cells and agonize the remaining PD-1+ T cells to restore the immune system back to a state of homeostasis. This is anticipated to result in specific immunological outcomes in both inflamed tissue and the periphery, such as reduction in T cell proliferation, migration and cytokine secretion, and reduction of plasma cell generation and autoantibody levels. Currently, the drug is in Phase II stage of its development for the treatment of Rheumatoid Arthritis (RA).

Leramistat: Istesso

Leramistat is an oral treatment that selectively modulates inflammation at the level of tissue damage, adapting to stimulus strength. By avoiding outright inhibition of inflammatory cytokine cascades and promoting a pro-repair environment, leramistat fine-tunes control of subclinical inflammation and restores normal bone dynamics to resolve rheumatoid pathology at its source. With its unique “pro-repair” mechanism, leramistat offers a new foundational option for combination therapy, enabling other disease-modifying treatments to work better for longer and elevating the definition of remission. Currently, the drug is in Phase II stage of its development for the treatment of Rheumatoid Arthritis (RA).

AP1189: Synact Pharma

SynAct Pharma’s drug candidate, resomelagon (AP1189), is a once-daily oral biased melanocortin receptor type 1 and 3 (MC1r and MC3r) agonist. The pharmacological effects of the compound are mediated by its ability to balance ongoing inflammation and bringing the immune system in a given inflamed tissue, organ, or circulation to a new homeostatic state with less proinflammatory activity and activation of pro-resolving pathways. This effect is distinct from suppression of the immune system, which may cause unwanted side effects, such as increased risk of infections and other side effects. The mode of action is specifically interesting to apply in active inflammation, including early active states of chronic inflammatory/autoimmune diseases and in hyperinflammatory states of infectious diseases where the benefit of applying immunosuppressive drugs is outweighed by the risk of use. The selectivity of resomelagon (AP1189) to MC1r and MC3r means that MC2r mediated glucocorticoid release from the adrenal gland is avoided. Thus, the compound induces its pharmacological effects in a steroid-free manner without the significant safety, tolerability, and side effect issues associated with adrenocorticotropic hormone (ACTH) based therapies. Further to that, the compound stimulates the MC1r through biased agonism, activating an alternative pathway, so the compound can be given without the unwanted side effect of skin hyperpigmentation that classical MC1r agonists will induce though cAMP activation in melanocytes. Currently, the drug is in Phase II stage of its development for the treatment of Rheumatoid Arthritis (RA).

LPX-TI641: LAPIX Therapeutics

LPX-TI641 is an oral, small-molecule designed to bind the phosphatidylserine binding pocket on the T cell/transmembrane, immunoglobulin, and mucin (Tim) family of receptors. It is currently under clinical development for autoimmune indications such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and multiple sclerosis with plans to expand to other autoimmune indications where the underlying pathology involves immune imbalances and loss of self-tolerance. LPX-TI641’s primary pharmacology works to restore the adaptive immune system’s self-tolerance rather than suppressing immunity, enabling patients to more effectively and gently combat autoimmune disease. Toxicological studies and emerging clinical data show that LPX-TI641 does not induce neutropenia or lymphocytopenia, suggesting a potentially improved safety profile compared to current therapies. Currently, the drug is in Phase I stage of its development for the treatment of Rheumatoid Arthritis (RA).

Explore groundbreaking therapies and clinical trials in the Rheumatoid Arthritis Pipeline @ New Rheumatoid Arthritis Drugs

The Rheumatoid Arthritis Pipeline Report Provides Insights into-

Rheumatoid Arthritis Companies

Gedeon Richter, mAbxience Research S.L., AnaptysBio, Inc, Istesso, Synact Pharma, Sanofi, AstraZeneca, Cullinan Therapeutics, Sonoma Biotherapeutics, Immunovant, Inc, Janssen Research & Development, LLC, Ernexa Therapeutics Inc., Kymera Therapeutics, Inc., Eli Lilly and Company, Rise Therapeutics LLC, Artiva Biotherapeutics, Inc., SinoMab BioScience Limited, ECM Therapeutics, Hangzhou Highlightll Pharmaceutical Co., Ltd, Beijing VDJBio Co., LTD., AbbVie, ILAb Co., Ltd., Sonoma Biotherapeutics, Inc., Gilead Sciences, Zenas BioPharma (USA), LLC, Flerie AB, Spyre Therapeutics, Inc, Candid Therapeutics, Inc., LAPIX Therapeutics and others.

Rheumatoid Arthritis (RA) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Rheumatoid Arthritis Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Learn about new drugs, Rheumatoid Arthritis Pipeline developments, and key companies with DelveInsight’s expert analysis @ Rheumatoid Arthritis Market Drivers and Barriers

Scope of the Rheumatoid Arthritis Pipeline Report

Coverage- Global
Rheumatoid Arthritis Companies- Gedeon Richter, mAbxience Research S.L., AnaptysBio, Inc, Istesso, Synact Pharma, Sanofi, AstraZeneca, Cullinan Therapeutics, Sonoma Biotherapeutics, Immunovant, Inc, Janssen Research & Development, LLC, Ernexa Therapeutics Inc., Kymera Therapeutics, Inc., Eli Lilly and Company, Rise Therapeutics LLC, Artiva Biotherapeutics, Inc., SinoMab BioScience Limited, ECM Therapeutics, Hangzhou Highlightll Pharmaceutical Co., Ltd, Beijing VDJBio Co., LTD., AbbVie, ILAb Co., Ltd., Sonoma Biotherapeutics, Inc., Gilead Sciences, Zenas BioPharma (USA), LLC, Flerie AB, Spyre Therapeutics, Inc, Candid Therapeutics, Inc., LAPIX Therapeutics and others.
Rheumatoid Arthritis Pipeline Therapies- BMS-582949, Etanercept, Lutikizumab, Ravagalimab, Filgotinib Maleate, IMVT-1402, TLL-018, CPL409116, LY3541860 and others.
Rheumatoid Arthritis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Rheumatoid Arthritis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Rheumatoid Arthritis Pipeline Therapies and clinical trials @ Rheumatoid Arthritis Companies, Key Products and Unmet Needs

Table of Contents

Introduction
Executive Summary
Rheumatoid Arthritis (RA): Overview
Pipeline Therapeutics
Therapeutic Assessment
Rheumatoid Arthritis (RA)– DelveInsight’s Analytical Perspective
Late Stage Products (Registration)
RGB-19: Gedeon Richter
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
AP1189: Synact Pharma
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
LPX-TI641: LAPIX Therapeutics
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Rheumatoid Arthritis (RA) Key Companies
Rheumatoid Arthritis (RA) Key Products
Rheumatoid Arthritis (RA)- Unmet Needs
Rheumatoid Arthritis (RA)- Market Drivers and Barriers
Rheumatoid Arthritis (RA)- Future Perspectives and Conclusion
Rheumatoid Arthritis (RA) Analyst Views
Rheumatoid Arthritis (RA) Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Rheumatoid Arthritis Pipeline Shows Strong Momentum as 75+ Pharma Companies in the Race | DelveInsight

Triple Negative Breast Cancer Clinical Trial Landscape Advances Rapidly as 165+ Companies Innovate in Targeted Biologic Therapies | DelveInsight

DelveInsight’s “Triple Negative Breast Cancer Pipeline Insight 2026” report provides comprehensive insights about 165+ companies and 170+ pipeline drugs in the Triple Negative Breast Cancer pipeline landscape. It covers the Triple Negative Breast Cancer Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Triple Negative Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead in understanding the Triple Negative Breast Cancer Treatment Landscape @ Triple Negative Breast Cancer Pipeline Outlook

Key Takeaways from the Triple Negative Breast Cancer Pipeline Report

On May 01, 2026- Merck Sharp & Dohme LLC initiated a phase 3 study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician’s choice (TPC) in participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery. The primary objective is to compare sacituzumab tirumotecan plus pembrolizumab to TPC (pembrolizumab or pembrolizumab plus capecitabine) with respect to invasive disease-free survival (iDFS) per investigator assessment. It is hypothesized that sacituzumab tirumotecan plus pembrolizumab is superior to TPC with respect to iDFS per investigator assessment.
On April 30, 2026- Gilead Sciences conducted a phase 3 study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician’s choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.
On April 29, 2026- Dana-Farber Cancer Institute initiated a research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative.
On April 27, 2026- Memorial Sloan Kettering Cancer Center announced a phase 2 study to find out whether the study drug, SDX-7320, when combined with the standard chemotherapy eribulin, is an effective treatment for people with TNBC and metabolic dysfunction. The researchers will also look at whether the study treatment (SDX-7320 combined with eribulin) is safe and causes few or mild side effects in participants. The researchers will compare this treatment approach to eribulin alone.
On April 24, 2026- AstraZeneca conducted a phase IB/II study is designed to determine the efficacy and safety of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple negative breast cancer
DelveInsight’s Triple Negative Breast Cancer Pipeline analysis depicts a robust space with 165+ active players working to develop 170+ pipeline treatment therapies.
The leading Triple Negative Breast Cancer Companies such as Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc, and others.
Promising Triple Negative Breast Cancer Pipeline Therapies such as Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Taxotere® (100 mg/m2), B013+Nab-Paclitaxel, ZEN003694, Talazoparib, Pembrolizumab, Sacituzumab Govitecan-hziy, Datopotamab Deruxtecan (Dato-DXd), and others.

Stay ahead with the most recent pipeline outlook for Triple Negative Breast Cancer @ Triple Negative Breast Cancer Treatment Drugs

Triple Negative Breast Cancer Overview

Triple Negative Breast Cancer (TNBC) is defined as a tumor where the estrogen and progesterone (ER/PR) are negative, as assessed by immunohistochemistry (IHC), and there is a lack of overexpression of HER2, as assessed by immunohistochemistry (IHC), or the absence of its gene amplification, as assessed by fluorescence in situ hybridization technique. The epidemiological risk factor profiles also vary between TNBC (ER-PR-HER2-) and other breast cancers. TNBCs are frequently identified as hyper dense masses without associated calcifications. The majority of TNBCs are histologically classified as high-grade, invasive, ductal carcinomas of no special type with basal-like features. Central necrosis, pushing tumor borders, a conspicuous lymphocytic infiltrate, and fibrosis are common histologic features.

Triple Negative Breast Cancer Emerging Drugs

Trilaciclib: G1 Therapeutics, Inc.

TofaciTrilaciclib, a transient IV-administered CDK4/6 inhibitor, is a novel therapeutic approach which is given before chemotherapy that temporarily blocks progression through the cell cycle. This provides two potential benefits firstly bone marrow protection and therefore the immune system from damage caused by cytotoxic therapy, and secondly improved long term immune surveillance by upregulating the formation of certain memory T cells. Trilaciclib is being evaluated a number of tumor types and chemotherapy regimens to assess its potential myeloprotection, antitumor efficacy and safety in combination with cytotoxic therapies and other anticancer agents. Currently, the drug is in the Phase III stage of its development for the treatment of Triple Negative Breast Cancer.

Olaparib: AstraZeneca

Olaparib is an oral PARP inhibitor developed by AstraZeneca, approved for BRCA-mutated triple-negative breast cancer (TNBC). It works by blocking PARP enzymes, preventing DNA repair in cancer cells, leading to cell death, particularly in BRCA1/2-mutant tumors. The OlympiAD trial showed that Olaparib significantly improved progression-free survival (PFS) compared to chemotherapy in metastatic TNBC. It is FDA-approved for germline BRCA-mutated, HER2-negative breast cancer and is being explored in combination with immunotherapy and chemotherapy for broader TNBC treatment. Currently, the drug is in the Phase II/III stage of its development for the treatment of Triple Negative Breast Cancer.

Patritumab Deruxtecan: Daiichi Sankyo Company/Merck

Patritumab deruxtecan (HER3-DXd) is an investigational HER3-directed antibody–drug conjugate (ADC) developed by Daiichi Sankyo. It comprises a fully human anti-HER3 monoclonal antibody linked to a topoisomerase I inhibitor payload via a tumor-selective cleavable linker. HER3 is frequently overexpressed in triple-negative breast cancer (TNBC), correlating with poorer prognosis. In a phase 1/2 trial, patritumab deruxtecan demonstrated promising clinical activity in patients with HER3-expressing metastatic breast cancer. Currently, the drug is in the Phase II stage of its development for the treatment of Triple Negative Breast Cancer.

NUV-868: Nuvation Bio Inc.

NUV-868 is an experimental drug being studied alone and in combination with PARP inhibitors for the treatment of advanced solid tumors, including triple-negative breast cancer (TNBC). Nuvation Bio had decided not to initiate a Phase II study of NUV-868 as a monotherapy or in combination with olaparib or enzalutamide in the advanced solid tumor indications that were part of the Phase I and Phase Ib study designs. The Company is evaluating next steps for the NUV-868 program, including further development in combination with approved products for indications in which BD2-selective BET inhibitors may improve outcomes for patients. Currently, the drug is in the Phase I/II stage of its development for the treatment of Triple Negative Breast Cancer.

TUB-030: Tubulis

TUB-030 is an antibody drug conjugate directed against 5T4, an oncofetal antigen, expressed in a broad range of solid tumor types. It consists of an IgG1 antibody targeting 5T4 connected to the Topoisomerase I inhibitor exatecan through a cleavable linker system based on the company’s proprietary P5 conjugation technology with a homogeneous DAR of 8. P5 conjugation is a novel chemistry for cysteine-selective conjugation that enables ADC generation with unprecedented linker stability and biophysical properties. Currently the drug is in Preclinical stage of its development for the treatment of TNBC.

The Triple Negative Breast Cancer Pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Triple Negative Breast Cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Triple Negative Breast Cancer Treatment.
Triple Negative Breast Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Triple Negative Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Triple Negative Breast Cancer market

Explore groundbreaking therapies and clinical trials in the Triple Negative Breast Cancer Pipeline @ New Triple Negative Breast Cancer Drugs

Triple Negative Breast Cancer Companies

Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc, and others.

Triple Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Triple Negative Breast Cancer Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Unveil the future of Triple Negative Breast Cancer Treatment @ Triple Negative Breast Cancer Market Drivers and Barriers

Scope of the Triple Negative Breast Cancer Pipeline Report

Coverage- Global
Triple Negative Breast Cancer Companies- Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc, and others.
Triple Negative Breast Cancer Pipeline Therapies- Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Taxotere® (100 mg/m2), B013+Nab-Paclitaxel, ZEN003694, Talazoparib, Pembrolizumab, Sacituzumab Govitecan-hziy, Datopotamab Deruxtecan (Dato-DXd), and others.
Triple Negative Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Triple Negative Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Triple Negative Breast Cancer Therapies and clinical trials @ Triple Negative Breast Cancer Companies, Key Products and Unmet Needs

Table of Content

Introduction
Triple Negative Breast Cancer Executive Summary
Triple Negative Breast Cancer: Overview
Triple Negative Breast Cancer Pipeline Therapeutics
Triple Negative Breast Cancer Therapeutic Assessment
Triple Negative Breast Cancer – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Camrelizumab: Jiangsu HengRui Medicine
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
AK117: Akeso Biopharma
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
PMD-026: Phoenix Molecular Designs
Drug profiles in the detailed report…..
Inactive Products
Triple Negative Breast Cancer Companies
Triple Negative Breast Cancer Products
Triple Negative Breast Cancer Unmet Needs
Triple Negative Breast Cancer Market Drivers and Barriers
Triple Negative Breast Cancer Future Perspectives and Conclusion
Triple Negative Breast Cancer Analyst Views
Triple Negative Breast Cancer Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Triple Negative Breast Cancer Clinical Trial Landscape Advances Rapidly as 165+ Companies Innovate in Targeted Biologic Therapies | DelveInsight

Obstructive Sleep Apnea Pipeline Shows Potential with Active Contributions from 18+ Key Companies | DelveInsight

DelveInsight’s “Obstructive Sleep Apnea Pipeline Insight 2026” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Obstructive Sleep Apnea pipeline landscape. It covers the Obstructive Sleep Apnea pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Obstructive Sleep Apnea pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Obstructive Sleep Apnea Pipeline? @ https://www.delveinsight.com/sample-request/obstructive-sleep-apnea-osa-pipeline-insight

Key Takeaways from the Obstructive Sleep Apnea Pipeline Report

On June 04, 2026- Amgen conducted a Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are not on PAP therapy and are living with overweight or obesity.
On June 04, 2026- Eli Lilly and Company announced a phase 3 studies is to evaluate the efficacy and safety of eloralintide in participants with moderate-to-severe obstructive sleep apnea and obesity or overweight. YDAO is a master protocol designed to support two independent studies: YSA1 and YSA2. Study YSA1 will include participants who are unable or unwilling to use Positive Airway Pressure (PAP) therapy and study YSA2 will include participants who are on PAP therapy for at least 3 months at time of screening and plan to continue PAP therapy during the study.
On June 02, 2026- Novo Nordisk A/S initiated a study is being done to look at the efficacy and safety of NNC0487-0111 in participants with excess body weight and obstructive sleep apnoea not treated with positive airway pressure lose weight and improve sleep apnoea. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111, (the treatment being tested) or Placebo (a treatment that has no active medicine in it) and which treatment participants get is decided by chance.
DelveInsight’s Obstructive Sleep Apnea Pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Obstructive Sleep Apnea treatment.
The leading Obstructive Sleep Apnea Companies such as Apnimed, Incannex Healthcare Ltd, Mineralys Therapeutics Inc., Eli Lilly and Company, Desitin Arzneimittel GmbH, Shionogi Apnimed Sleep Science and others.
Promising Obstructive Sleep Apnea Therapies such as Sulthiame, AD128, Mannitol, AD313, AVE0657, Eszopiclone, BAY2586116, Atomoxetine, BAY2253651, AD504, Atomoxetine, R-oxybutynin and others.

Want to know which companies are leading innovation in Obstructive Sleep Apnea? @ Obstructive Sleep Apnea Clinical Trials Assessment

The Obstructive Sleep Apnea Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Obstructive Sleep Apnea Pipeline Report also highlights the unmet needs with respect to the Obstructive Sleep Apnea.

Obstructive Sleep Apnea Overview

Obstructive Sleep Apnea (OSA) is a common sleep-related breathing disorder characterized by repeated partial or complete obstruction of the upper airway during sleep. This obstruction leads to disrupted airflow despite ongoing respiratory effort, causing shallow breathing (hypopnea) or brief pauses in breathing (apnea). As a result, oxygen levels may drop, and the body responds by briefly awakening the individual, often with a gasp, snort, or sudden movement. OSA is frequently associated with loud snoring and fragmented, non-restorative sleep. Common symptoms include excessive daytime sleepiness, morning headaches, dry mouth or sore throat, difficulty concentrating, mood changes, night sweats, restless sleep, and may also be linked to Gastroesophageal Reflux Disease (GERD).

Obstructive Sleep Apnea Emerging Drugs Profile

AD109: Apnimed

AD109 is an investigational, once-daily oral therapy being developed for the treatment of Obstructive Sleep Apnea (OSA), targeting the neuromuscular mechanisms responsible for upper airway collapse during sleep. It acts on the Hypoglossal Motor Nucleus to enhance upper airway dilator muscle activity, thereby helping maintain airway patency and improving oxygen levels. This first-in-class anti-apneic neuromuscular modulator combines aroxybutynin (an antimuscarinic agent) and atomoxetine (a selective norepinephrine reuptake inhibitor) to achieve synergistic therapeutic effects. Designed as a convenient bedtime pill, AD109 is currently under Phase III clinical evaluation as a non-invasive treatment option for patients with mild to severe OSA.

HRS9531: Jiangsu Hengrui Pharmaceuticals Co., Ltd.

HRS9531 is an investigational therapeutic agent being explored for the treatment of Obstructive Sleep Apnea (OSA), with a focus on addressing underlying metabolic and physiological contributors to the condition. It is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist designed to promote weight loss and improve metabolic health, which are key factors in OSA severity. By reducing body weight and potentially decreasing upper airway obstruction, HRS9531 may help improve breathing patterns during sleep. Currently, the drug is under Phase III clinical evaluation for the treatment of OSA.

If you’re tracking ongoing Obstructive Sleep Apnea Clinical trials, this press release is a must-read @ Obstructive Sleep Apnea Treatment Drugs

The Obstructive Sleep Apnea Pipeline report provides insights into:-

The report provides detailed insights about companies that are developing therapies for the treatment of Obstructive Sleep Apnea with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Obstructive Sleep Apnea Treatment.
Obstructive Sleep Apnea Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Obstructive Sleep Apnea Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Obstructive Sleep Apnea market.

Obstructive Sleep Apnea Companies

Apnimed, Incannex Healthcare Ltd, Mineralys Therapeutics Inc., Eli Lilly and Company, Desitin Arzneimittel GmbH, Shionogi Apnimed Sleep Science and others.

Obstructive Sleep Apnea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Obstructive Sleep Apnea Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

From emerging drug candidates to competitive intelligence, the Obstructive Sleep Apnea Pipeline Report covers it all @ Obstructive Sleep Apnea Market Drivers and Barriers, and Future Perspectives

Scope of the Obstructive Sleep Apnea Pipeline Report

Coverage- Global
Obstructive Sleep Apnea Companies- Apnimed, Incannex Healthcare Ltd, Mineralys Therapeutics Inc., Eli Lilly and Company, Desitin Arzneimittel GmbH, Shionogi Apnimed Sleep Science and others.
Obstructive Sleep Apnea Therapies- Sulthiame, AD128, Mannitol, AD313, AVE0657, Eszopiclone, BAY2586116, Atomoxetine, BAY2253651, AD504, Atomoxetine, R-oxybutynin and others.
Obstructive Sleep Apnea Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Obstructive Sleep Apnea Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the Obstructive Sleep Apnea Treatment landscape in this detailed analysis @ Obstructive Sleep Apnea Emerging Drugs and Major Players

Table of Contents

Introduction
Executive Summary
Obstructive Sleep Apnea: Overview
Pipeline Therapeutics
Therapeutic Assessment
Obstructive Sleep Apnea (OSA)– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
AD109: Apnimed
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
MOS118: Mosanna Therapeutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Drug Name: Company Name
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Obstructive Sleep Apnea Key Companies
Obstructive Sleep Apnea Key Products
Obstructive Sleep Apnea- Unmet Needs
Obstructive Sleep Apnea- Market Drivers and Barriers
Obstructive Sleep Apnea- Future Perspectives and Conclusion
Obstructive Sleep Apnea Analyst Views
Obstructive Sleep Apnea Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Obstructive Sleep Apnea Pipeline Shows Potential with Active Contributions from 18+ Key Companies | DelveInsight

Sjogren’s Syndrome Market is Projected to Grow Significantly by 2036 Owing to the Launch of Emerging Disease-Modifying Therapies | DelveInsight

The market dynamics for Sjogren’s Syndrome are witnessing steady growth driven by the increasing prevalence of autoimmune disorders, rising awareness regarding early diagnosis, growing burden of chronic dry eye and dry mouth conditions, and increasing demand for effective disease-modifying therapies. Additionally, the launch of emerging therapies such as Ianalumab (VAY736), Dazodalibep (VIB4920), Telitacicept, Nipocalimab, and others will further fuel the market.

DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Sjogren’s Syndrome Market Insights, Epidemiology, and Market Forecast 2036.” This comprehensive report provides an in-depth understanding of Sjogren’s Syndrome, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Sjogren’s Syndrome Market

The market size for Sjogren’s Syndrome in the leading markets is expected to grow significantly by 2036.
The United States accounted for the highest Sjogren’s Syndrome treatment market size in 7MM in 2025, in comparison to the other major markets, i.e., EU4 countries, the United Kingdom, and Japan.
As per DelveInsight’s analysis, in 2025, the total diagnosed prevalent cases of Sjogren’s Syndrome were approximately 3,350,000 in the 7MM, which are expected to increase during the forecast period, i.e., 2026–2036.
In 2025, the diagnosed prevalent cases of Sjogren’s Syndrome were the highest in the US accounting for approximately 1,800,000 cases which are estimated to increase by 2036.
According to the Sjogren’s Syndrome Foundation (US), it is one of the second most common autoimmune rheumatic diseases, striking as many as 4,000,000 Americans.
Approximately one percent of the US population is affected with Sjogren’s Syndrome, wherein mostly adult women are affected. Nine out of 10 patients are women.
According to the study conducted by Stefanski et al. (2017), the overall prevalence of Sjogren’s Syndrome, including the more common secondary form of the disease, is estimated to be at least 0.4% in Germany.
According to the Japan Intractable Diseases Information Center, approximately 68,000 patients were admitted to hospitals for one year for Sjogren’s Syndrome in Japan.
Leading Sjogren’s Syndrome companies such as Novartis, Amgen, Vor Bio, Resolve Therapeutics, Johnson & Johnson, and others are developing new Sjogren’s Syndrome treatment drugs that can be available in the Sjogren’s Syndrome market in the coming years.
The promising Sjogren’s Syndrome therapies in clinical trials include Ianalumab (VAY736), Dazodalibep (VIB4920), Telitacicept, Nipocalimab, RSLV-132, AMG 329, and others.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/sjogrens-syndrome-market-size

Key Factors Driving the Sjogren’s Syndrome Market

Rising Disease Prevalence and Awareness: Increasing diagnosis rates, growing awareness regarding autoimmune diseases, and advancements in diagnostic approaches are helping identify more Sjogren’s Syndrome patients globally.
Increasing Demand for Effective Disease-Modifying Therapies: Currently available therapies mainly focus on symptom management, creating a strong demand for disease-modifying therapies capable of improving long-term outcomes and reducing systemic complications.
Growing Focus on Biological Therapies and Novel Mechanisms: Several emerging therapies targeting BAFF, CD40L, FcRn, and APRIL pathways are being developed to improve disease management and reduce inflammatory burden in Sjogren’s Syndrome patients.
Advancements in Diagnostic and Supportive Care Approaches: Improved use of salivary gland biopsy, salivary gland ultrasound, and biomarker-driven diagnosis are contributing to better disease detection and treatment optimization.

Sjogren’s Syndrome Competitive Landscape

Several Sjogren’s Syndrome drugs in development include Ianalumab (VAY736), Dazodalibep (VIB4920), Telitacicept, Nipocalimab, RSLV-132, and AMG 329.
These candidates target diverse mechanisms such as BAFF-R inhibition and ADCC-mediated B-cell depletion, CD40 ligand inhibition, BAFF/APRIL targeting, anti-FcRn mechanisms, and RNAse therapy, aiming to improve symptoms and disease progression with better efficacy and safety profiles than current treatment options.

Discover more about therapies set to grab major Sjogren’s Syndrome market share @ Sjogren’s Syndrome Treatment Landscape

Recent Developments in the Sjogren’s Syndrome Market

In March 2025, Johnson & Johnson announced that the US FDA granted investigational nipocalimab Fast Track designation for the treatment of adult patients with moderate-to-severe Sjogren’s disease.
In November 2023, Amgen presented new data from the Phase II trial of dazodalibep in Sjogren’s Syndrome at ACR 2023.
In June 2025, Vor Bio and RemeGen announced an exclusive license agreement granting Vor Bio global rights to develop and commercialize telitacicept outside China, Hong Kong, Macau, and Taiwan.
Ianalumab (VAY736) developed by Novartis is currently in Phase III developmental stage for Primary Sjogren’s Syndrome.

What is Sjogren’s Syndrome?

Sjogren’s Syndrome is a chronic autoimmune disorder characterized by the immune system attacking moisture-producing glands, leading primarily to dry eyes and dry mouth. The disease can also affect multiple organs including joints, lungs, kidneys, nerves, and blood vessels. Patients commonly experience fatigue, joint pain, dental complications, and an increased risk of lymphoma. Disease severity varies significantly among individuals, ranging from mild glandular involvement to severe systemic manifestations.

Sjogren’s Syndrome Epidemiology Segmentation

The Sjogren’s Syndrome epidemiology section provides insights into the historical and current Sjogren’s Syndrome patient pool and forecasted trends for the leading markets. The Sjogren’s Syndrome market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

Total Diagnosed Prevalent Cases of Sjogren’s Syndrome
Type-specific Cases of Sjogren’s Syndrome
Gender-specific Cases of Sjogren’s Syndrome
Severity-specific Cases of Sjogren’s Syndrome
Antigen-specific Cases of Sjogren’s Syndrome
Total Treated Cases of Sjogren’s Syndrome

Scope of the Sjogren’s Syndrome Market Report

Therapeutic Assessment: Sjogren’s Syndrome current marketed and emerging therapies
Sjogren’s Syndrome Market Dynamics: Key Market Forecast Assumptions of Emerging Sjogren’s Syndrome Drugs and Market Outlook
Key Companies: Novartis, Amgen, Vor Bio, Resolve Therapeutics, Johnson & Johnson, and others
Key Therapies: Ianalumab (VAY736), Dazodalibep (VIB4920), Telitacicept, Nipocalimab, RSLV-132, AMG 329, SALAGEN, EVOXAC, and others
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, Sjogren’s Syndrome Market Access and Reimbursement

To know more about Sjogren’s Syndrome companies working in the treatment market, visit @ Sjogren’s Syndrome Clinical Trials and Therapeutic Assessment

Table of Contents

Sjogren’s Syndrome Market Report Introduction
Executive Summary for Sjogren’s Syndrome
SWOT Analysis of Sjogren’s Syndrome
Sjogren’s Syndrome Patient Share (%) Overview at a Glance
Sjogren’s Syndrome Market Overview at a Glance
Sjogren’s Syndrome Background and Overview
Sjogren’s Syndrome Epidemiology and Patient Population
Country-Specific Patient Population of Sjogren’s Syndrome
Sjogren’s Syndrome Current Treatment and Medical Practices
Sjogren’s Syndrome Unmet Needs
Sjogren’s Syndrome Emerging Therapies
Sjogren’s Syndrome Market Outlook
Country-Wise Sjogren’s Syndrome Market Analysis (2022–2036)
Sjogren’s Syndrome Market Access and Reimbursement of Therapies
Sjogren’s Syndrome Market Drivers
Sjogren’s Syndrome Market Barriers
Sjogren’s Syndrome Appendix
Sjogren’s Syndrome Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Sjogren’s Syndrome Market is Projected to Grow Significantly by 2036 Owing to the Launch of Emerging Disease-Modifying Therapies | DelveInsight

Chronic Myeloid Leukemia Market is Projected to Grow Significantly by 2034 Owing to the Launch of Emerging Therapies | DelveInsight

The market dynamics for Chronic Myeloid Leukemia (CML) are witnessing substantial growth driven by the increasing incidence of CML, growing adoption of targeted therapies, rising awareness regarding molecular diagnostics, and advancements in tyrosine kinase inhibitor (TKI) therapies. Additionally, the launch of emerging therapies such as ELVN-001, TERN-701, olverembatinib (HQP1351), and others will further boost the market growth.

DelveInsight, a leading market research firm, has released its latest report, “DelveInsight’s Chronic Myeloid Leukemia (CML) Market Insights, Epidemiology, and Market Forecast 2034.” The report provides a comprehensive understanding of CML, including historical and forecasted epidemiology, market trends, current treatment landscape, and emerging therapies across the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Key Takeaways from the Chronic Myeloid Leukemia (CML) Market

The Chronic Myeloid Leukemia market size in the 7MM is expected to grow significantly during the forecast period (2025–2034).
The United States accounted for the largest CML market size among the 7MM in 2025, compared to EU4 countries, the United Kingdom, and Japan.
According to DelveInsight’s estimates, the CML market size in the 7MM was approximately USD 235 million in 2020, which is projected to increase significantly by 2034.
According to SEER, the number of new CML cases in the US is expected to be around 9,560 in 2025.
According to the American Cancer Society, approximately 9,560 new cases of CML are expected to be diagnosed in the United States in 2025, including 5,610 cases in men and 3,950 cases in women.
As per the SEER database, the rate of new CML cases was 2.0 per 100,000 men and women per year based on 2018–2022 cases.
According to the study conducted by Qingqing Lin et al. (2020), approximately 34,179 incident cases of CML and 24,054 CML-related deaths were reported globally in 2017.
According to the study by Elias Jabbour et al. (2018), CML is a myeloproliferative neoplasm with an incidence of 1–2 cases per 100,000 adults.
Leading CML companies such as Enliven Therapeutics, Terns Pharmaceuticals, Ascentage Pharma, Takeda Pharmaceuticals, AOP Orphan Pharmaceuticals, Novartis, and others are developing novel therapies for the treatment of CML.
Promising therapies in the CML pipeline include ELVN-001, TERN-701, olverembatinib (HQP1351), BESREMi (ropeginterferon alfa 2b), and others.

Want to know more about the market? Visithttps://www.delveinsight.com/sample-request/chronic-myeloid-leukemia-market

Key Factors Driving the Chronic Myeloid Leukemia (CML) Market

Increasing Incidence of CML: Rising incident cases of CML globally are contributing significantly to market growth.
Advancements in Targeted Therapies: The development and adoption of next-generation tyrosine kinase inhibitors (TKIs) with improved efficacy and tolerability profiles are transforming CML treatment paradigms.
Growing Demand for Personalized Treatment Approaches: Regular molecular testing and mutation profiling are improving therapy selection and treatment outcomes.
Emergence of Novel Therapies: Pipeline candidates such as ELVN-001, TERN-701, and olverembatinib are expected to improve treatment outcomes in resistant or intolerant CML patients.
Improved Diagnostic Technologies: Increasing use of cytogenetic analysis, FISH, and RT-PCR testing for BCR-ABL1 detection is supporting early diagnosis and treatment optimization.

Chronic Myeloid Leukemia (CML) Competitive Landscape

Several emerging therapies are currently under clinical development for the treatment of CML, including ELVN-001, TERN-701, olverembatinib (HQP1351), BESREMi, and others.
These therapies focus on advanced BCR-ABL inhibition mechanisms, allosteric kinase inhibition, improved selectivity, and better safety profiles to address resistance, intolerance, and long-term disease management challenges in CML patients.

Learn more about the therapies expected to capture significant CML market share @ CML Treatment Landscape

Recent Developments in the Chronic Myeloid Leukemia (CML) Market

In November 2025, Enliven Therapeutics announced that it would present data from the ongoing ENABLE Phase Ia/Ib clinical trial of ELVN-001 in patients with atypical fusion transcript CML at the 67th ASH Annual Meeting 2025.
In June 2025, Enliven Therapeutics presented updated positive Phase I ENABLE trial data for ELVN-001 at the European Hematology Association (EHA) 2025 Congress.
In December 2025, Ascentage Pharma presented updated data on olverembatinib in second-line treatment of chronic-phase CML patients at ASH 2025.
In December 2025, Terns Pharmaceuticals announced updated and expanded data from the ongoing CARDINAL trial of TERN-701 in previously treated CML patients at ASH 2025.
In October 2024, the US FDA granted accelerated approval to asciminib for adult patients with newly diagnosed Philadelphia chromosome-positive chronic-phase CML.
In September 2023, the US FDA approved BOSULIF for pediatric patients aged 1 year or older with chronic-phase Philadelphia chromosome-positive CML that is newly diagnosed or resistant/intolerant to prior therapy.

What is Chronic Myeloid Leukemia (CML)?

Chronic Myeloid Leukemia (CML) is a type of blood and bone marrow cancer characterized by the excessive production of abnormal white blood cells due to the presence of the BCR-ABL1 fusion gene, commonly known as the Philadelphia chromosome. CML typically progresses slowly and is classified into chronic, accelerated, and blast phases. The disease is primarily treated using tyrosine kinase inhibitors (TKIs), which target the abnormal BCR-ABL protein and help patients achieve long-term disease control.

Chronic Myeloid Leukemia (CML) Epidemiology Segmentation

The CML epidemiology section provides insights into historical and forecasted patient pools and epidemiology trends across the 7MM during the study period 2020–2034. The report segments the epidemiology into:

Total Incident Cases of CML
Total Symptomatic Incident Cases of CML
Incident Cases of CML by Phases (Chronic, Accelerated, and Blast)
Age-specific Incident Cases of CML
Mutation-specific Incident Cases of CML

Scope of the Chronic Myeloid Leukemia (CML) Market Report

Therapeutic Assessment: CML current and emerging therapies
CML Market Dynamics: Key Market Forecast Assumptions and Market Outlook
Key Companies: Enliven Therapeutics, Terns Pharmaceuticals, Ascentage Pharma, Takeda Pharmaceuticals, AOP Orphan Pharmaceuticals, Novartis, and others
Key Therapies: ELVN-001, TERN-701, olverembatinib (HQP1351), BESREMi, SCEMBLIX, ICLUSIG, BOSULIF, and others
Competitive Intelligence Analysis: SWOT analysis and market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, Market Access and Reimbursement

To know more about companies working in the CML treatment market, visit @ CML Clinical Trials and Emerging Therapies

Table of Contents

Chronic Myeloid Leukemia (CML) Market Report Introduction
Executive Summary of CML
SWOT Analysis of CML
CML Epidemiology and Market Forecast Methodology
CML Market Overview at a Glance
Disease Background and Overview of CML
CML Epidemiology and Patient Population
Country-specific Patient Population of CML
CML Current Treatment and Medical Practices
CML Emerging Therapies
CML Market Outlook
Country-wise CML Market Analysis (2020–2034)
CML Market Access and Reimbursement
CML Market Drivers
CML Market Barriers
Appendix
Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve business performance. DelveInsight’s subscription-based platform PharmDelve offers seamless access to healthcare and pharma market research reports.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Myeloid Leukemia Market is Projected to Grow Significantly by 2034 Owing to the Launch of Emerging Therapies | DelveInsight

Radioligand Therapy Market is Expected to Grow Rapidly by 2036, Estimates DelveInsight

Key companies like Novartis, Curium Pharma, Lantheus, Eli Lilly and Company, Fusion Pharmaceuticals, AstraZeneca, Clarity Pharmaceuticals, Bayer, ITM Isotope Technologies, ARTBIO, Convergent Therapeutics, Perspective Therapeutics, PRECIRIX, Ariceum Therapeutics, Nuclidium, and others are leading the exponential growth in the market.

DelveInsight’s “Radioligand Therapy Market Size, Target Population, Competitive Landscape, and Market Forecast – 2036” report delivers an in-depth understanding of Radioligand Therapy, historical and forecasted epidemiology as well as the Radioligand Therapy market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Interested to know which radioligand therapy will capture the highest market share, download the report to understand the Radioligand Therapy market update @ https://www.delveinsight.com/report-store/radioligand-therapies-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=akpr

Key Takeaways from the Radioligand Therapy Market Report

The Radioligand Therapy market across the 7MM is expected to witness significant growth during the forecast period, driven by increasing cancer prevalence, growing demand for targeted oncology treatments, and the emergence of novel therapies for indications like metastatic castration-resistant prostate cancer (mCRPC) and gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Emerging therapies such as 177Lu-PSMA-I&T, Lu-PNT2002, FPI-2265, 225Ac-PSMA-Trillium, VMT-α-NET, CONV01-α, and others are expected to intensify competition by offering differentiated radioisotope mechanisms, improved targeting precision, and the potential to expand treatment access across broader cancer indications.
Gene therapies and next-generation alpha-emitting radioligand candidates are attracting substantial industry interest due to their potential to deliver superior cytotoxicity through highly targeted radiation while minimizing damage to surrounding healthy tissues.
LUTATHERA recorded more than USD 450 million in sales in the first nine months of 2023, with a growth rate of 34% year over year, and Novartis believes LUTATHERA could notch more than USD 1 billion in peak sales as a first-line therapy.
Upon approval in 2022, PLUVICTO generated full-year sales of USD 980 million, narrowly missing blockbuster status in its first full year on the market.
The leading Radioligand Therapy companies include Novartis, Curium Pharma, Lantheus, Eli Lilly and Company, Fusion Pharmaceuticals, AstraZeneca, Clarity Pharmaceuticals, Bayer, ITM Isotope Technologies, ARTBIO, Convergent Therapeutics, Perspective Therapeutics, PRECIRIX, Ariceum Therapeutics, Nuclidium, and others.
Despite recent therapeutic advances, substantial unmet needs remain in radioligand therapy, including treatment access for chemotherapy-naïve patients, expansion to rare cancer types, and development of next-generation alpha-emitting therapies, creating significant opportunities for pipeline developers and investors.

Gain a competitive edge in the Radioligand Therapy Market by exploring our in-depth analysis @ Radioligand Therapy Treatment Drugs –https://www.delveinsight.com/sample-request/radioligand-therapies-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=akpr

Radioligand Therapy Marketed Drugs

The marketed Radioligand Therapy landscape is rapidly evolving following the introduction of novel targeted radiopharmaceuticals for oncology indications. The approval and commercial launch of these products has validated the market’s potential and paved the way for next-generation therapies with differentiated mechanisms, improved targeting precision, and broader cancer coverage.

LUTATHERA (lutetium Lu 177 dotatate): AAA USA/Novartis

LUTATHERA is the first radioligand therapy approved specifically for children with gastroenteropancreatic neuroendocrine tumors (GEP-NETs), now offering new hope to young patients living with this rare cancer. It is also approved in Europe for unresectable or metastatic, progressive, well-differentiated (G1 and G2), SSTR-positive GEP-NETs in adults, and in Japan for SSTR-positive NETs. LUTATHERA works by binding to somatostatin receptors present in certain tumors; after binding, the drug enters the cell allowing radiation to damage tumor cells. In 2018, the US FDA first approved LUTATHERA, making it the first radiopharmaceutical approved for GEP-NETs, and in 2024, the FDA further approved it for pediatric patients with GEP-NETs.

PLUVICTO (lutetium lu-177 vipivotide tetraxetan): Novartis

PLUVICTO is the first FDA-approved targeted radioligand therapy (RLT) for eligible patients with metastatic castration-resistant prostate cancer (mCRPC) that combines a targeting compound (ligand) with a therapeutic radioisotope. The active moiety of lutetium Lu 177 vipivotide tetraxetan is the radionuclide lutetium-177, which is linked to a moiety that binds to PSMA, a transmembrane protein expressed in prostate cancer, including mCRPC. Upon binding to PSMA-expressing cells, the beta-minus emission from lutetium-177 delivers radiation to those cells and surrounding cells, inducing DNA damage that can lead to cell death. PLUVICTO was approved by the FDA in 2022 and recorded sales of more than USD 950 million in its first full year on the market.

Radioligand Therapy Emerging Drugs

177Lu-PSMA-I&T: Curium

177Lu-PSMA-I&T targets prostate-specific membrane antigen (PSMA), which is expressed in greater than 85% of prostate cancer cells. Because the medicine is highly selective for that antigen, the radioisotope only targets these cancer cells. Once the medicine attaches itself to the cancer cell, the radioisotope is internalized within the cancer cell, where the radioactive properties break the DNA strand of the cancer cells, thus killing the prostate cancer cell. The therapy is currently in Phase III clinical development.

Lu-PNT2002: Eli Lilly/Point Biopharma

Lu-PNT2002 is a PSMA-targeted, lutetium 177-based radioligand therapy candidate that combines a PSMA-targeted ligand, PSMA-I&T, with the beta-emitting radioisotope no-carrier-added lutetium-177. Lantheus Holdings holds exclusive worldwide commercialization rights (excluding certain Asian territories) to 177Lu-PNT2002 from POINT, in-licensed in December 2022. In April 2023, the FDA granted Fast Track designation for 177Lu-PNT2002 for the treatment of mCRPC. The therapy is currently in Phase III clinical development and is anticipated to receive approval during the forecast period.

Download the report to understand which factors are driving Radioligand Therapy Epidemiology Trends @ Radioligand Therapy Prevalence

Latest Highlights from the Radioligand Therapy Market

In March 2026, ITM Isotope Technologies Munich SE presented post-hoc subgroup analyses from the Phase 3 ITM-11 COMPETE trial involving patients with Grade 1 or Grade 2 somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
In March 2026, Lantheus Holdings, Inc. announced that the FDA had granted tentative approval to its Abbreviated New Drug Application (ANDA) for Lutetium Lu 177 Dotatate (PNT2003), a radioequivalent version of LUTATHERA (lutetium Lu 177 dotatate).
In January 2026, Zonsen PepLib Biotech Inc. announced a global licensing agreement with Novartis for an undisclosed peptide-based candidate in the radioligand therapy (RLT) space, with Novartis securing exclusive worldwide rights for development and commercialization.
In January 2026, Swiss Rockets AG and Alloy Therapeutics, Inc. entered into a Master Research Agreement (MRA) to initiate a multi-target partnership focused on the discovery and development of next-generation radioligand therapeutics (RLTs) for oncology, to be carried out through Swiss Rockets’ radiotherapeutics subsidiary, Torpedo Pharmaceuticals AG.
In January 2026, ARTBIO, Inc. began dosing two US-based patient cohorts in the ARTISAN Phase 1 trial of AB001, an alpha radioligand therapy designed to treat metastatic castration-resistant prostate cancer (mCRPC), enrolling patients with and without prior Lu177-PSMA targeted therapy exposure.
In November 2025, ITM Isotope Technologies Munich SE announced that the US Food and Drug Administration had completed its filing review and accepted the company’s New Drug Application (NDA) for n.c.a. 177Lu-edotreotide, also referred to as ITM-11.

Discover key developments and opportunities in the Radioligand Therapy Market @ Radioligand Therapy Market Size

Radioligand Therapy Companies

Radioligand Therapy Companies include Novartis, Curium Pharma, Lantheus, Eli Lilly and Company, Fusion Pharmaceuticals, AstraZeneca, Clarity Pharmaceuticals, Bayer, ITM Isotope Technologies, ARTBIO, Convergent Therapeutics, Perspective Therapeutics, PRECIRIX, Ariceum Therapeutics, Nuclidium, and others.

Radioligand Therapy Market Outlook

The treatment landscape for Radioligand Therapy has historically been limited to conventional modalities such as chemotherapy and external radiation, with limited options for patients with advanced or metastatic disease. The approved therapies – LUTATHERA, PLUVICTO, XOFIGO, and ZEVALIN – represent a paradigm shift toward precision oncology by delivering targeted radiation directly to cancer cells expressing specific receptors, while minimizing damage to surrounding healthy tissues.

The pipeline for Radioligand Therapy is rapidly evolving, with emerging therapies focusing on novel radioisotopes and broader cancer targets beyond PSMA and somatostatin receptors. 177Lu-PSMA-I&T and Lu-PNT2002 target PSMA-expressing prostate cancer cells with high selectivity, while FPI-2265 by Fusion Pharmaceuticals and AstraZeneca expands the mCRPC treatment frontier further into Phase II/III development. Alpha-emitting radioligand candidates such as 225Ac-PSMA-Trillium and CONV01-α highlight a broader shift toward next-generation radioisotopes with greater cytotoxic potential. Novartis alone has 15+ radioligand therapy clinical trials underway or planned, and major acquisitions – including AstraZeneca’s acquisition of Fusion Pharmaceuticals and Eli Lilly’s USD 1.4 billion acquisition of Point Biopharma – underscore the growing strategic importance of this therapeutic class. Overall, the emergence of both approved radioligand therapies and a diverse pipeline of targeted candidates marks a significant transition from conventional cancer treatment to highly targeted, disease-modifying radioligand strategies.

Scope of the Radioligand Therapy Market Report

Coverage: 7MM

Study Period: 2022–2036

Radioligand Therapy Companies: Novartis, Curium Pharma, Lantheus, Eli Lilly and Company, Fusion Pharmaceuticals, AstraZeneca, Clarity Pharmaceuticals, Bayer, ITM Isotope Technologies, ARTBIO, Convergent Therapeutics, Perspective Therapeutics, PRECIRIX, Ariceum Therapeutics, Nuclidium, and others.

Radioligand Therapy Pipeline Therapies: 177Lu-PSMA-I&T, Lu-PNT2002, FPI-2265, 225Ac-PSMA-Trillium, 225Ac-Pelgifatamab, VMT-α-NET, VMT01, CONV01-α, CAM-FAP-Ac-225, ITM-11, AB001, NU101, NU201, and others.

Radioligand Therapy Competitive Intelligence Analysis: SWOT analysis, Conjoint analysis, and Market entry strategies.

Radioligand Therapy Unmet Needs, KOL’s views, Analyst’s views, Radioligand Therapy Market Access and Reimbursement.

Table of Contents

Key Insights
Report Introduction
Executive Summary of Radioligand Therapies
Key Events
Radioligand Therapies Market Overview At A Glance
Background And Overview
Target Population
Radioligand Therapies Marketed Drugs
Radioligand Therapies Emerging Drugs
Radioligand Therapies: The 7MM Analysis
Unmet Needs
SWOT Analysis
KOL Views
Radioligand Therapy Market Access and Reimbursement
Appendix
DelveInsight Capabilities
Disclaimer
About DelveInsight

How DelveInsight’s Radioligand Therapy Market Report Helps CXOs and Business Leaders

Evaluate the current and future market opportunity across the United States, EU4, the United Kingdom, and Japan through detailed epidemiology and market forecasts.
Benchmark emerging radioligand therapy assets through comprehensive competitive intelligence, pipeline assessment, clinical trial analysis, and probability of success evaluation.
Identify potential licensing, acquisition, co-development, and partnership opportunities by tracking key innovators and late-stage pipeline assets, including recent high-value transactions such as the Eli Lilly–Point Biopharma and AstraZeneca–Fusion Pharmaceuticals acquisitions.
Assess the impact of upcoming clinical readouts, regulatory milestones, and expected launches on future market share, pricing, reimbursement, and commercial strategy.
Support strategic decision-making with insights into KOL perspectives, unmet needs, treatment algorithms, patient segmentation, and evolving market dynamics across the Radioligand Therapy landscape.

About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/radioligand-therapies-market-forecast

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Radioligand Therapy Market is Expected to Grow Rapidly by 2036, Estimates DelveInsight